細胞色素P450 19抗體-抗體-抗體-生物在線
上海雅吉生物科技有限公司
細胞色素P450 19抗體

細胞色素P450 19抗體

商家詢價

產品名稱： 細胞色素P450 19抗體

英文名稱： Aromatase

產品編號： 1292

產品價格： null

產品產地： 上海

品牌商標： 雅吉

更新時間： null

使用范圍： WB ELISA IHC-P IHC-F Flow-Cyt ICC IF

上海雅吉生物科技有限公司
  • 聯系人 :
  • 地址 : 上海市閔行區元江路5500號第1幢5658室
  • 郵編 :
  • 所在區域 : 上海
  • 電話 : 158****3937 點擊查看
  • 傳真 : 點擊查看
  • 郵箱 : yajikit@163.com

?

中文名稱 細胞色素P450 19抗體
別????名 Cytochrome p450 19A1; Estrogen synthetase; ARO 1; ARO; ARO1; CPV; CYPXIX; Cytochrome P450 family 19 subfamily A polypeptide 1; MGC104309; P 450AROM; P450AROM; CP19A_HUMAN; Cytochrome P-450AROM; CPV1; CYAR; CYP19; Cyp19a1; Cytochrome P450, family 19, subfamily A, polypeptide 1; Cytochrome P450, subfamily XIX (aromatization of androgens); Flavoprotein linked monooxygenase; Microsomal monooxygenase; OTTHUMP00000162543; OTTHUMP00000198350; P 450AROM.??

?

研究領域 腫瘤??細胞生物??
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應 Human,?Rat,? (predicted: Mouse,?Dog,?Pig,?Cow,?Horse,?Rabbit,?Sheep,?)
產品應用 WB=1:500-2000?ELISA=1:500-1000?IHC-P=1:100-500?IHC-F=1:100-500?Flow-Cyt=1μg/Test?ICC=1:100-500?IF=1:100-500?（石蠟切片需做抗原修復）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分?子?量 58kDa
細胞定位 細胞膜?
性????狀 Liquid
濃????度 1mg/ml
免?疫?原 KLH conjugated synthetic peptide derived from human CYP19:41-140/503?
亞????型 IgG
純化方法 affinity purified by Protein A
儲?存?液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件 Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
PubMed PubMed
產品介紹 This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and catalyzes the last steps of estrogen biosynthesis, three successive hydroxylations of the A ring of androgens. Mutations in this gene can result in either increased or decreased aromatase activity; the associated phenotypes suggest that estrogen functions both as a sex steroid hormone and in growth or differentiation. The gene expresses two transcript variants. Belongs to the cytochrome P450 family.

Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.

Subcellular Location:
Membrane; Peripheral membrane protein.

Tissue Specificity:
Brain, placenta and gonads.

DISEASE:
Defects in CYP19A1 are a cause of aromatase excess syndrome (AEXS) [MIM:139300]; also known as familial gynecomastia. AEXS is characterized by an estrogen excess due to an increased aromatase activity.
Defects in CYP19A1 are the cause of aromatase deficiency (AROD) [MIM:613546]. AROD is a rare disease in which fetal androgens are not converted into estrogens due to placental aromatase deficiency. Thus, pregnant women exhibit a hirsutism, which spontaneously resolves after post-partum. At birth, female babies present with pseudohermaphroditism due to virilization of extern genital organs. In adult females, manifestations include delay of puberty, breast hypoplasia and primary amenorrhoea with multicystic ovaries.

Similarity:
Belongs to the cytochrome P450 family.

SWISS:
P11511

Gene ID:
1588

Database links:

Entrez Gene: 1588?Human

Entrez Gene: 13075?Mouse

Entrez Gene: 25147?Rat

Omim: 107910?Human

SwissProt: P11511?Human

SwissProt: P28649?Mouse



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

芳香化酶基因(CYP19)編碼的芳香化酶是催化雄激素向雌激素轉化的關鍵酶,CYP19的變異可使芳香化酶活性改變,導致雌激素水平的改變,從而使乳腺癌易感性發生改變,也可能影響到乳腺癌內分泌治療的敏感性。
目前關于CYP19基因多態性與乳腺癌之間的關系仍存在爭論,尚需深入研究以明確芳香化酶的基因多態性在乳腺癌發生中的作用,以及該基因多態性對芳香化酶功能的影響。
產品圖片 Sample:HepG2 Cell Lysate at 40 ug
Primary: Anti- CYP19 (bs-1292R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 58 kD
Observed band size: 60 kD
Tissue/cell: human placenta tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-CYP19/CYP19A1 Polyclonal Antibody, Unconjugated(bs-1292R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Tissue/cell: rat brain tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-CYP19/CYP19A1 Polyclonal Antibody, Unconjugated(bs-1292R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Blank control: RSC96 (blue).
Primary Antibody:Rabbit Anti- CYP19 antibody(bs-1292R), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA;
Isotype Control Antibody: Rabbit IgG(orange) ,used under the same conditions );
Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA.
Protocol
The cells were fixed with 2% paraformaldehyde (10 min). Primary antibody (bs-1292R, 1μg /1x10^6 cells) were incubated for 30 min on the ice, followed by 1 X PBS containing 0.5% BSA + 1 0% goat serum (15 min) to block non-specific protein-protein interactions. Then the Goat Anti-rabbit IgG/PE antibody was added into the blocking buffer mentioned above to react with the primary antibody at 1/200 dilution for 30 min on ice. Acquisition of 20,000 events was performed.

?